TY - JOUR
T1 - R-Loop Accumulation in Spliceosome Mutant Leukemias Confers Sensitivity to PARP1 Inhibition by Triggering Transcription–Replication Conflicts
AU - Liu, Zhiyan Silvia
AU - Sinha, Sayantani
AU - Bannister, Maxwell
AU - Song, Axia
AU - Arriaga-Gomez, Erica
AU - McKeeken, Alexander J.
AU - Bonner, Elizabeth A.
AU - Hanson, Benjamin K.
AU - Sarchi, Martina
AU - Takashima, Kouhei
AU - Zong, Dawei
AU - Corral, Victor M.
AU - Nguyen, Evan
AU - Yoo, Jennifer
AU - Chiraphapphaiboon, Wannasiri
AU - Leibson, Cassandra
AU - McMahon, Matthew C.
AU - Rai, Sumit
AU - Swisher, Elizabeth M.
AU - Sachs, Zohar
AU - Chatla, Srinivas
AU - Stirewalt, Derek L.
AU - Deeg, H. Joachim
AU - Skorski, Tomasz
AU - Papapetrou, Eirini P.
AU - Walter, Matthew J.
AU - Graubert, Timothy A.
AU - Doulatov, Sergei
AU - Lee, Stanley C.
AU - Nguyen, Hai Dang
N1 - Publisher Copyright:
©2023 American Association for Cancer Research.
PY - 2024
Y1 - 2024
N2 - RNA splicing factor (SF) gene mutations are commonly observed in patients with myeloid malignancies. Here we showed that SRSF2- and U2AF1-mutant leukemias are preferentially sensitive to PARP inhibitors (PARPi), despite being proficient in homologous recombination repair. Instead, SF-mutant leukemias exhibited R-loop accumulation that elicited an R-loop-associated PARP1 response, rendering cells dependent on PARP1 activity for survival. Consequently, PARPi induced DNA damage and cell death in SF-mutant leukemias in an R-loop-dependent manner. PARPi further increased aberrant R-loop levels, causing higher transcription-replication collisions and triggering ATR activation in SF-mutant leukemias. Ultimately, PARPi-induced DNA damage and cell death in SF-mutant leukemias could be enhanced by ATR inhibition. Finally, the level of PARP1 activity at R-loops correlated with PARPi sensitivity, suggesting that R-loop-associated PARP1 activity could be predictive of PARPi sensitivity in patients harboring SF gene mutations. This study highlights the potential of targeting different R-loop response pathways caused by spliceosome gene mutations as a therapeutic strategy for treating cancer.
AB - RNA splicing factor (SF) gene mutations are commonly observed in patients with myeloid malignancies. Here we showed that SRSF2- and U2AF1-mutant leukemias are preferentially sensitive to PARP inhibitors (PARPi), despite being proficient in homologous recombination repair. Instead, SF-mutant leukemias exhibited R-loop accumulation that elicited an R-loop-associated PARP1 response, rendering cells dependent on PARP1 activity for survival. Consequently, PARPi induced DNA damage and cell death in SF-mutant leukemias in an R-loop-dependent manner. PARPi further increased aberrant R-loop levels, causing higher transcription-replication collisions and triggering ATR activation in SF-mutant leukemias. Ultimately, PARPi-induced DNA damage and cell death in SF-mutant leukemias could be enhanced by ATR inhibition. Finally, the level of PARP1 activity at R-loops correlated with PARPi sensitivity, suggesting that R-loop-associated PARP1 activity could be predictive of PARPi sensitivity in patients harboring SF gene mutations. This study highlights the potential of targeting different R-loop response pathways caused by spliceosome gene mutations as a therapeutic strategy for treating cancer.
UR - http://www.scopus.com/inward/record.url?scp=85185223420&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-23-3239
DO - 10.1158/0008-5472.CAN-23-3239
M3 - Article
C2 - 37967363
AN - SCOPUS:85185223420
SN - 0008-5472
VL - 84
SP - 577
EP - 597
JO - Cancer research
JF - Cancer research
IS - 4
ER -